Lamivudine 100 mg once a day for 52 weeks

2 trials

Sponsors

BRISTOL MYERS SQUIBB PERU S.A.,

Unknown Phase

PHASE III STUDY ON THE SECURITY AND ANTIVIRAL ACTIVITY OF ENTECAVIR VS. LAMIVUDINE IN ADULTS WITH INFECTION WITH CHRONIC HEPATITIS B AND POSITIVE FOR ANTIGENE E OF HEPATITIS B

Active, not recruitingPER-041-01

BRISTOL MYERS SQUIBB PERU S.A.,

Updated: 2023-09-04

PHASE III STUDY ON THE SECURITY AND ANTIVIRAL ACTIVITY OF ENTECAVIR VS. LAMIVUDINE IN ADULTS WITH INFECTION WITH CHRONIC HEPATITIS B AND NEGATIVES FOR ANTIGENE E OF HEPATITIS B

Active, not recruitingPER-044-01

BRISTOL MYERS SQUIBB PERU S.A.,

Updated: 2023-09-04